INTRODUCTION Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist approved by the U.S. Federal Drug Administration for the treatment of "moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause." Although published, peer-reviewed, placebo-controlled studies have shown objective improvement in dyspareunia and in vaginal atrop...

OBJECTIVE We sought to compare the development of paraurethral banding and subsequent dyspareunia in women undergoing either a transobturator (TO) or retropubic (RP) sling. STUDY DESIGN We conducted a retrospective cohort study comparing women treated with either a TO or RP sling during a 10-month period. RESULTS A total of 25 TO sling patients and 28 RP sling patients were compared in the ...

T he clinical presentation of dyspareunia is often perplexing; patients may be difficult to assess, and positive clinical findings are not always observed on standard gynecologic examination. Adding to the confusion, the American Psychiatric Association’s Diagnostic and Statistical Manual defines dyspareunia as a sexual condition rather than a pain disorder, implying a psychogenic origin.1,2 Pa...

Purpose: To assess the efficacy of a non-invasive, site-specific manual physiotherapeutic technique in ameliorating dyspareunia and dysmenorrhea, commonly associated with endometriosis, by performing a retrospective and prospective analysis, respectively. Methods: Human female subjects, all surgically diagnosed with endometriosis, were enrolled in each of the studies post informed consent. Each...

www.aafp.org/afp AMERICAN FAMILY PHYSICIAN 1535 Epidemiology There are few reports of clinical trials relating to dyspareunia, and much of the literature derives from expert opinion. The lack of a single etiology for the pain contributes to the diagnostic difficulty. The incidence of dyspareunia depends on the definition used and the population sampled. In a national probability sample assessin...

The DSM-IV-TR (American Psychiatric Association, 2000) classifies dyspareunia as a sexual dysfunction and describes it as a "sexual pain" disorder. This classification has been widely accepted with little controversy despite the absence of a theoretical rationale or supporting empirical data. An examination of the validity of this classification suggests that there is little current justificati...